hcp.mykybella.com
hcp.mykybella.com Profile
hcp.mykybella.com
Maindomain:mykybella.com
Title:
Description:COVID-19 SUPPORT During this uncertain time, one thing remains certain—our commitment to supporting you. Click here for COVID-19 resources for your practice. X This site is intended for US healthcar
Discover hcp.mykybella.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
hcp.mykybella.com Information
Website / Domain: |
hcp.mykybella.com |
HomePage size: | 23.646 KB |
Page Load Time: | 0.102949 Seconds |
Website IP Address: |
3.227.183.236 |
Isp Server: |
General Electric Company |
hcp.mykybella.com Ip Information
Ip Country: |
United States |
City Name: |
Fairfield |
Latitude: |
41.218349456787 |
Longitude: |
-73.251731872559 |
hcp.mykybella.com Keywords accounting
hcp.mykybella.com Httpheader
Cache-Control: no-cache, no-store |
Content-Encoding: gzip |
Content-Type: text/html; charset=utf-8 |
Date: Fri, 05 Feb 2021 08:14:34 GMT |
Expires: -1 |
Pragma: no-cache |
Server: |
Set-Cookie: ASP.NET_SessionId=k1vcbhf53kyhfbwrhd1hw1u1; path=/; HttpOnly; SameSite=Lax, SC_ANALYTICS_GLOBAL_COOKIE=9e885de8b6224fada5992a93ee4bfc93|False; path=/; HttpOnly |
Vary: Accept-Encoding |
X-Content-Type-Options: nosniff |
Content-Length: 6400 |
Connection: keep-alive |
hcp.mykybella.com Meta Info
charset="utf-8"/ |
content="width=device-width, initial-scale=1.0" name="viewport"/ |
content="" name="keywords"/ |
content="" name="title"/ |
content="" name="description"/ |
3.227.183.236 Domains
hcp.mykybella.com Similar Website
hcp.mykybella.com Traffic Sources Chart
hcp.mykybella.com Alexa Rank History Chart
hcp.mykybella.com Html To Plain Text
COVID-19 SUPPORT During this uncertain time, one thing remains certain—our commitment to supporting you. Click here for COVID-19 resources for your practice. X This site is intended for US healthcare professionals. Important safety information Prescribing Information For consumers ABOUT SUBMENTAL FULLNESS ABOUT KYBELLA ® CLINICAL STUDY DESIGN CLINICAL RESULTS SAFETY PROFILE MECHANISM OF ACTION ABOUT TREATMENT BEFORE & AFTER FAQs TRAINING SET UP ACCOUNT NOW YOU SEE IT. NOW YOU DON , T. BEFORE AFTER Unretouched photos of paid models. Individual results may vary. Female patient: Age: 35 BMI (before/after): 25.2/25.5 Male patient: Age: 36 BMI (before/after): 26.6/26.3 Number of treatments is tailored* to the amount of submental fat and aesthetic goals; 59% of subjects received 6 KYBELLA ® treatments in clinical trials. 1 *Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart. 1 KYBELLA ® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. 1 The safe and effective use of KYBELLA ® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. 1 BEFORE & AFTER See results of patients treated with KYBELLA ® injection. Individual results may vary. VIEW INDIVIDUALLY TAILORED* KYBELLA ® INJECTIONS For adults with moderate to severe submental fat (double chin): KYBELLA ® permanently destroys fat cells in the treatment area under the chin for an improved profile. *Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart. MORE GET TRAINED TODAY Register to watch the Online Training Video to become a trained KYBELLA ® injector. REGISTER ABOUT KYBELLA ® The first-of-its-kind FDA-approved injectable, KYBELLA ® is a nonsurgical option to improve the appearance of submental fullness in adults. MORE Before & Afters See the noticeable results and improved chin profile of patients treated with KYBELLA ® . VIEW Individual results may vary. INDICATION KYBELLA ® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA ® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS KYBELLA ® is contraindicated in the presence of infection at the injection sites. WARNINGS AND PRECAUTIONS Marginal Mandibular Nerve Injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA ® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. Dysphagia Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA ® in patients with current or prior history of dysphagia as treatment may exacerbate the condition. Injection-Site Hematoma/Bruising In clinical trials, 72% of subjects treated with KYBELLA ® experienced hematoma/bruising. KYBELLA ® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures To avoid the potential of tissue damage, KYBELLA ® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury. Injection Site Alopecia Cases of injection site alopecia have been reported with administration of KYBELLA ® . Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution. Injection Site Ulceration and Necrosis Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA ® . Do not administer KYBELLA ® into affected area until complete resolution. ADVERSE REACTIONS The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration. Please see KYBELLA ® full Prescribing Information . Reference: 1 . KYBELLA ® Prescribing Information, May 2020. Privacy Statement California Privacy Policy Prescribing Information Terms of Use Corporate Site Contact Us ™ © 2020 Allergan. All rights reserved. All trademarks are the property of their respective owners. KYB70304_v6 06/20 006731 Important safety information Prescribing Information For consumers About submental fullness About kybella Clinical Study Design Clinical Results Safety Profile Mechanism Of Action About Treatment before & After Faq Training SETUP ACCOUNT...
hcp.mykybella.com Whois
"domain_name": [
"MYKYBELLA.COM",
"mykybella.com"
],
"registrar": "MarkMonitor, Inc.",
"whois_server": "whois.markmonitor.com",
"referral_url": null,
"updated_date": [
"2021-01-11 23:38:30",
"2021-02-16 21:32:28-08:00"
],
"creation_date": [
"2014-05-15 16:25:03",
"2014-05-15 09:25:03-07:00"
],
"expiration_date": [
"2021-05-15 16:25:03",
"2021-05-15 00:00:00-07:00"
],
"name_servers": [
"HA1.MARKMONITOR.ZONE",
"HA2.MARKMONITOR.ZONE",
"HA3.MARKMONITOR.ZONE",
"HA4.MARKMONITOR.ZONE",
"ha1.markmonitor.zone",
"ha2.markmonitor.zone",
"ha3.markmonitor.zone",
"ha4.markmonitor.zone"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited)",
"clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited)",
"clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited)"
],
"emails": [
"abusecomplaints@markmonitor.com",
"internetnameregistrar@abbvie.com",
"whoisrequest@markmonitor.com"
],
"dnssec": "unsigned",
"name": "Domain Administrator",
"org": "AbbVie Inc.",
"address": "1 North Waukegan Road,",
"city": "North Chicago",
"state": "IL",
"zipcode": "60064",
"country": "US"